ARCHIVES

Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans

This article is from The Cancer Letter archive.

Vol. 03 No. 46 | November 18, 1977

Download PDF Visit The Full Archive

Related Articles

Heidelberger Wins $100,000 Award

September 17, 1982

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

December 27, 2013

California Hospital Raises $22 Million For New Cancer Center

September 14, 1990

Nexavar Phase III Trial Fails To Meet Primary Endpoint

June 29, 2012

Nixon National Cancer Conference Kicks Off

December 8, 2021

In Brief: No More Shifts Planned For Treatment Programs; Groups Seek Surgeon, Radiologist Incentives

August 29, 1975